Similarly, the expression of the Cldn1 and TGF-β genes in the PBMCs of HCC patients was markedly higher than that in the PBMCs of non-malignant patients by up to 3.6- and 2.95-fold, respectively. This evidence concerns the gene CLDN1 and hepatocellular carcinoma.